Trials / Unknown
UnknownNCT03553303
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Oslo University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacubitril / Valsartan Oral Tablet | Increasing doses of Sacubitril/Valsartan |
Timeline
- Start date
- 2018-10-16
- Primary completion
- 2022-05-01
- Completion
- 2022-05-01
- First posted
- 2018-06-12
- Last updated
- 2019-08-29
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT03553303. Inclusion in this directory is not an endorsement.